Amgen (AMGN) Tops Q2 EPS by 29c

Amgen (NASDAQ: AMGN) reported Q2 EPS of $3.83, $0.29 better than the analyst estimate of $3.54. Revenue for the quarter came in at $6.06 billion versus the consensus estimate of $5.73 billion.

GUIDANCE:

Amgen sees FY2018 EPS of $13.30-$14.00, versus the consensus of $13.75. Amgen sees FY2018 revenue of $22.5-23.2 billion, versus the consensus of $22.59 billion.

Sees CapEx at $750 million

For earnings history and earnings-related data on Amgen (AMGN) click here.

You May Also Be Interested In

• MillerKnoll, Inc. (MLKN) Tops Q1 EPS by 18c ; Offers Guidance
• AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR DAZODALIBEP IN MODERATE-TO-SEVERE SYSTEMIC SJÖGREN'S DISEASE
• CRH plc (CRH) PT Lowered to $135 at UBS, Buy Rating Maintained